Cancer Focus Fund Appoints Distinguished Industry Experts David R. Epstein and Michael Margolis as Advisors to Its Investment Committee
Epstein and Margolis bring decades of business expertise and industry leadership to Cancer Focus Fund as it prepares for Its next round of investments.
ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center
First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies
Promising early signals of activity seen as Phase 1 dose escalation proceeds
Cancer Focus Fund Invests $5.1 Million in Starget Pharma to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy
Starget Pharma will use investment to move into clinical trials at MD Anderson and other cancer centers.
March Biosciences Closes Oversubscribed $28.4 Million Series A Financing
March Bio has raised over $51 million to date inclusive of all dilutive and non-dilutive funding. The Cancer Focus Fund was among initial investors and parcipated in a second round.
Eisbach Bio doses first patient in Phase 1/2 Trial for first-in-class drug to take on Refractory Advanced Solid Tumors
The trial is being conducted at The University of Texas MD Anderson Cancer Center and is co-funded by Cancer Focus Fund.
Immunome bets on Nectin’s antibodies for next-generation antibody drug conjugates
The collaboration aligns with Immunome's strategy of pursuing under-explored targets for cancer drugs.
Can Investors Both Earn Returns and End Cancer?
Billions are pouring into cancer treatments around the world, so investors and funders discuss how institutional investors can access returns.
Cancer Focus Fund invests $4.5 million in Eisbach Bio
Cancer Focus Fund is investing $4.5 million to support a Phase 1/2 clinical trial of Eisbach’s Bio lead candidate, EIS-12656, which will be conducted at MD Anderson. The drug candidate targets hard-to-treat tumors.
Nectin Adds Combination Therapy and Expands Clinical Trial Sites
Nectin Therapeutics Adds Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent.
The Cancer Focus Fund has invested in Nectin Therapeutics